Leaving drug discovery and moving to scale up and pilot plant applications often means larger batch sizes and higher quantity of API being manipulated. For high potency applications especially, the quantity of powder can make a low toxicity drug a major threat to safety. Introducing larger and higher capacity equipment such as blenders, lyophilizers and ovens requires an evaluation of the risk assessment to insure personnel and/or product safety.